Unigene ties up with Nordic for peptide meds in blockbuster markets

Building on its banner pacts with GlaxoSmithKline and upstart Tarsa Therapeutics, Unigene Laboratories ($UGNE) has joined forces with Danish biotech Nordic Bioscience to develop Unigene's oral peptide drugs in the big-time diseases type 2 diabetes, osteoarthritis and osteoporosis. On the top of that deal, Nordic Chairman Dr. Claus Christensen is supplying up to $6 million ($1.5 million to start) in equity investment through a foundation. The deal and investment fuel Unigene CEO Ashleigh Palmer's mission of rebooting the drug-delivery specialist with a pipeline of novel peptide drugs that can be taken orally rather than given via injection like most protein therapies. Article

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.